Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Chest

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/CHEST.130.5.1503PMID 17099030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence and Economic Burden of Bronchiectasis

  2005cited by this paper
• A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.

  2005cited by this paper
• Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.

  2001cited by this paper
• An investigation into causative factors in patients with bronchiectasis.

  2000cited by this paper
• Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.

  2000cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

  1999cited by this paper
• A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis.

  1999cited by this paper
• The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis.

  1998cited by this paper
• Microbiology of sputum from patients at cystic fibrosis centers in the United States.

  1998cited by this paper
• Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

  1997cited by this paper
• Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

  1996cited by this paper
• The response of patients with purulent bronchiectasis to antibiotics for four months.

  1988cited by this paper
• Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation.

  1986cited by this paper
• Effect of short and long term antibiotic response on lung function in bronchiectasis.

  1986cited by this paper

• Inhaled tobramycin in non-cystic fibrosis bronchiectasis: A meta-analysis of randomized controlled trials.

  2025cites this paper
• Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects

  2025cites this paper
• Inhaled antibiotics and non-cystic fibrosis bronchiectasis: Trying to solve the puzzle

  2025cites this paper
• Management erwachsener Patientinnen und Patienten mit Bronchiektasen-Erkrankung

  2024cites this paper
• Bronchiectasis Exacerbations: Are We Doing Everything We Can?

  2024cites this paper
• Size-tailored and acid-degradable polyvinyl alcohol microgels for inhalation therapy of bacterial pneumonia.

  2024cites this paper
• Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension

  2024cites this paper
• The efficacy and safety of inhaled antibiotics for pneumonia: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Systemic antibiotics for Pseudomonas aeruginosa infection in outpatients with non-hospitalised exacerbations of pre-existing lung diseases: a randomised clinical trial

  2024cites this paper
• Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens.

  2024cites this paper
• Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

  2024cites this paper
• Inhaleddry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection.

  2024cites this paper
• Association between Clinical Characteristics and Microbiota in Bronchiectasis Patients Based on Metagenomic Next-Generation Sequencing Technology

  2024cites this paper
• Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery

  2022cites this paper
• Antibiotic Management in Bronchiectasis.

  2022cites this paper
• Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis

  2022cites this paper
• Bronchiectasis and inhaled tobramycin: A literature review.

  2022cites this paper
• A Double-blind Randomized Placebo-controlled Phase-3 Trial of Tobramycin Inhalation Solution in Adults with Bronchiectasis with Pseudomonas aeruginosa Infection.

  2022cites this paper
• Indian Guidelines on Nebulization Therapy.

  2022cites this paper
• Reducing Pseudomonas sputum density in bronchiectasis

  2021cites this paper
• Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.

  2021cites this paper
• Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial

  2021cites this paper
• Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

  2020cites this paper
• Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease

  2020cites this paper
• Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

  2020cites this paper
• Диагностика и лечение бронхоэктазов. Рекомендации Испанского общества пульмонологов и торакальных хирургов (SEPAR) Diagnosis and treatment of bronchiectasis. Recommendations of the Spanish Society of Pneumology and Thoracic Surgery

  2020cites this paper
• Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.

  2020cites this paper
• Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study

  2020cites this paper
• Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

  2019cites this paper
• Experiencia con colistina nebulizada en pacientes con bronquiectasias no fibrosis quística colonizadas por Pseudomonas aeruginosa

  2019cites this paper
• Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.

  2019cites this paper
• Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis.

  2019cites this paper
• Duration of Antibiotic Therapy in Non-cystic Fibrosis Bronchiectasis

  2019cites this paper
• Hot topics and current controversies in non-cystic fibrosis bronchiectasis

  2019cites this paper
• Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study

  2019cites this paper
• Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients

  2019cites this paper
• Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials

  2019cites this paper
• Brazilian consensus on non-cystic fibrosis bronchiectasis

  2019cites this paper
• Long-Term Inhaled Antibiotic Treatment in Bronchiectasis

  2018cites this paper
• Oral versus inhaled antibiotics for bronchiectasis.

  2018cites this paper
• A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation

  2018cites this paper
• RECOMMENDATIONS OF THE SPANISH SOCIETY OF PULMONOLOGY AND THORACIC SURGERY ( SEPAR ) Diagnosis and Treatment of Bronchiectasis

  2018cites this paper
• Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis

  2018cites this paper
• Investigational inhaled therapies for non-CF bronchiectasis

  2018cites this paper
• Dual antibiotics for bronchiectasis.

  2018influential citation
• Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis––experiences from recent clinical trials

  2018cites this paper
• Head-to-head trials of antibiotics for bronchiectasis.

  2018cites this paper
• Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• Nebulized Antibiotics in Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis: Shifting the Goal Posts or a Post Too Far?

  2018cites this paper
• EVIEW ew advances in the therapy of non-cystic fibrosis bronchiectasis

  2018cites this paper
• British Thoracic Society Guideline for bronchiectasis in adults

  2018cites this paper
• Bacterial Flora in Sputum and Antibiotic Sensitivity in Exacerbations of Bronchiectasis

  2018cites this paper
• CHANG Bronchiectasis : Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• The pharmacological treatment of bronchiectasis

  2018cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2018cites this paper
• New therapies for the prevention and treatment of exacerbations of bronchiectasis

  2017cites this paper
• Inhaled Drug Therapy 2016: The Year in Review

  2017cites this paper
• University of Dundee European Respiratory Society guidelines for the management of adult bronchiectasis Polverino,

  2017cites this paper
• European Respiratory Society guidelines for the management of adult bronchiectasis

  2017cites this paper
• The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis

  2017influential citation
• Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis

  2017cites this paper
• Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research

  2017cites this paper
• Exacerbation of Bronchiectasis

  2017cites this paper
• Non-cystic fibrosis bronchiectasis: treatment and prevention of pulmonary exacerbations

  2017cites this paper
• Non-cystic fibrosis bronchiectasis

  2017cites this paper
• Inhaled antibiotics in chronic airway infections

  2017cites this paper
• Non Cystic Fibrosis Bronchiectasis : Diagnosis and Management

  2017cites this paper
• Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

  2017influential citation
• Bronchitis, Bronchiectasis

  2016cites this paper
• Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients

  2016cites this paper
• Diagnóstico y manejo de las agudizaciones de bronquiectasias

  2016cites this paper
• Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in patients with non-cystic fibrosis bronchiectasis

  2016cites this paper
• The clinical management of lower respiratory tract infections

  2016cites this paper
• Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients

  2016cites this paper
• Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration

  2016cites this paper
• Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives

  2016influential citation
• Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis.

  2016cites this paper
• Development of Liposomal Ciprofloxacin to Treat Lung Infections

  2016cites this paper
• Inhaled Antibiotics for Gram-Negative Respiratory Infections

  2016cites this paper
• Efficacy and safety of long‐term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta‐analysis

  2016cites this paper
• Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

  2016cites this paper
• Inhaled antibiotics in non-cystic fibrosis bronchiectasis: A meta-analysis.

  2016cites this paper
• Challenges in the development of new therapies for bronchiectasis

  2015cites this paper
• Genetics, diagnosis and future treatment strategies for primary ciliary dyskinesia

  2015cites this paper
• Developing drug therapies in bronchiectasis

  2015cites this paper
• Emerging Opportunities for Inhaled Antibiotic Therapy

  2015cites this paper
• Inhalation von Antibiotika bei nicht durch Mukoviszidose bedingter Bronchiektasie

  2015cites this paper
• Tuberculosis and its sequelae: Diagnostic, epidemiological and therapeutic studies

  2015cites this paper
• Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

  2015cites this paper
• Inflammatory Responses, Spirometry, and Quality of Life in Subjects With Bronchiectasis Exacerbations

  2015cites this paper
• New advances in the therapy of non-cystic fibrosis bronchiectasis

  2015cites this paper
• Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis

  2015cites this paper
• Inhaled antimicrobial therapy - barriers to effective treatment.

  2015cites this paper
• Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis

  2015influential citation
• Inhaled Formulation Design for the Treatment of Lung Infections.

  2015cites this paper
• Versorgung von Patienten mit Non-CF-Bronchiektasen in der niedergelassenen Praxis

  2014cites this paper
• Infectiologie respiratoire: Lung infections

  2014cites this paper
• Efficacy of Ciprofloxacin-Clarithromycin Combination Against Drug-Resistant Pseudomonas aeruginosa Mature Biofilm Using In Vitro Experimental Model

  2014cites this paper
• Pharmacotherapy for lower respiratory tract infections

  2014cites this paper
• Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead

  2014cites this paper